AstraZeneca’s Lynparza slows advanced breast cancer progression -study

June 4, 2017

Women with advanced breast cancer who carry specific genetic mutations experienced double the response rate and delayed disease progression when treated with AstraZeneca Plc (NYSE: AZN – news) ‘s Lynparza compared with standard chemotherapy, according to data from a late-stage trial presented on Sunday. In the study of 302 patients with inherited mutations of the

Continue Reading